Related Experiment Video

Updated: Jun 10, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Antibody-drug conjugates: targeted drug delivery for cancer

Stephen C Alley1, Nicole M Okeley, Peter D Senter

  • 1Seattle Genetics, Inc., 21823 30th Drive SE, Bothell, WA 98021, United States. SAlley@seagen.com

Current Opinion in Chemical Biology
|July 21, 2010
PubMed

Insights

Antibody-drug conjugates (ADCs) show promise in cancer therapy due to targeted drug delivery. Recent advances in ADCs have led to increased clinical trials for various lymphomas and breast cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Background:

  • The field of antibody-drug conjugates (ADCs) has advanced significantly.
  • Progress is attributed to optimizing mAb specificity, drug potency, linker technology, and drug conjugation.
  • Pre-clinical studies demonstrate targeted delivery of high intratumoral drug concentrations with minimal exposure to non-target tissues.

Purpose of the Study:

  • To review recent pre-clinical and clinical advances in the antibody-drug conjugate field.
  • To highlight key developments driving the increased clinical testing of ADCs.

Main Methods:

  • Review of pre-clinical biodistribution and pharmacokinetic studies.
  • Analysis of recent clinical trial data for antibody-drug conjugates.

Main Results:

  • Optimized ADC parameters lead to effective targeted drug delivery.
  • High intratumoral drug concentrations achieved with reduced systemic toxicity.
  • Three ADCs (brentuximab vedotin, Trastuzumab-DM1, Inotuzumab ozogamicin) are in late-stage clinical trials for Hodgkin lymphoma, breast cancer, and non-Hodgkin lymphoma, respectively.

Conclusions:

  • Antibody-drug conjugate technology is rapidly advancing.
  • Targeted delivery strategies are improving therapeutic efficacy and safety profiles.
  • Increased clinical development signifies the growing potential of ADCs in cancer treatment.

More Related Videos

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.